PCI Biotech – Winner of both DnB NOR’s Innovation prize 2011 and the People’s award

Posted on Sep 7, 2011

Oslo, Norway, 7 September 2011 – At a ceremony at DnB NOR in Oslo on 6 September 2011, PCI Biotech was awarded both the prestigious DnB NOR’s Innovation prize 2011 and the Peoples award. The Innovation prize of NOK 1,000.000 was handed over by Rune Bjerke, CEO of DnB NOR and the Peoples award of […]

Last patient included in the Phase I/II study of PC-A11

Posted on Feb 25, 2011

Oslo, 23 February 2011 – PCI Biotech (PCIB) the Norwegian biopharmaceutical company, reported today that it has completed the inclusion of patients in its phase I/II study of its lead candidate PC-A11 in cancer patients. The last patient has been treated with the company’s proprietary photosensitiser Amphinex® used in combination with the cytotoxic agent bleomycin […]